Empirical Ventures

MitoRx Therapeutics is a preclinical stage biotechnology company developing first-in-class mitochondrial-targeted small molecule therapeutics aimed at addressing obesity and other cardiometabolic diseases. Their innovative platform focuses on modulating mitochondrial metabolism to achieve weight loss while preserving lean mass.

Argonaute RNA develops SiRNA drugs for cardiometabolic diseases, leveraging a team with extensive experience from leading pharmaceutical companies.

We leverage leading-edge technologies to create highly targeted small molecule treatments.

Healome Therapeutics is a clinical stage company developing treatments for eye conditions, particularly ocular surface diseases and injuries. They utilize a proprietary eye drop technology aimed at improving drug retention, lubrication, and protection at the ocular surface.

Baseimmune is pioneering the next generation of active immunotherapies by combining cutting-edge computational design with advanced protein engineering. Our platform creates bespoke antigens that address the complexity of chronic diseases, unlocking new possibilities where traditional approaches fall short.

Anaphite is focused on revolutionizing battery production through its Dry Coating Precursor (DCP®) technology, which aims to reduce costs and carbon emissions in the manufacturing of EV batteries.

WASE specializes in next-generation waste-to-energy technology, focusing on maximizing biogas production through innovative anaerobic digestion solutions. Their modular systems are designed to treat waste efficiently while reducing costs and environmental impact.

QV Bioelectronics develops implantable devices to enhance brain tumor treatment, focusing on glioblastoma, by delivering targeted electric fields to disrupt cancer cell division.

Neuronostics is a UK-based medical technology company specializing in digital biomarkers for neurological conditions, notably epilepsy. The company aims to revolutionize diagnosis and treatment of neurological conditions through its patented technology.

Bioscience investor translating grant-funded research into venture-scale companies, with a pipeline centered on engineering biology using robotic cloud labs and computational design for human health and planetary sustainability. The firm grew directly out of a philanthropic grants program at the Thiel Foundation that funded highly speculative science before spinning into a traditional venture fund.

Founded in 2002, +ND invests in disruptive technologies spanning life, physical, and data sciences, prioritizing opportunities driven by scientific convergence.

Invests in disruptive, technology-focused startups; established in 1999.

Stealthy investor across frontier sectors (space, biotech, AI) making sub-$500K average checks into technically complex startups with exceptional defensibility and operational guidance from GP Rob Ness's 2% Rule.

Very-early investor using an impact-arbitrage strategy in high-impact companies, combining a solo-GP and 42 global venture partners to secure 69% top-tier follow-ons while pursuing top-decile returns and social impact.